HPS1329-95
141758-74-9
默认>95%HPLC,若需其他规格请洽询
产品编号 | 规格 | 货期 | 销售价 | 折扣价 | 数量 | 操作 |
---|---|---|---|---|---|---|
HPS1329-95 | 默认>95%HPLC,若需其他规格请洽询 |
25天
|
敬请询价 | 敬请询价 |
|
名字 | Exenatide acetate salt |
---|---|
序列(三字母) | H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂ acetate salt |
序列(单字母) | HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH₂ |
CAS# | 141758-74-9 |
分子式 | C₁₈₄H₂₈₂N₅₀O₆₀S |
分子量 | 4186.63 |
纯度 | 默认>95%HPLC,若需其他规格请洽询 |
合成方法 | Synthetic |
储存条件 | -20 ± 5 °C |
应用 | Diabetes|Parkinson’s Disease|Veterinary Medicine |
描述 | Exendin-4 (exenatide), originally isolated from Heloderma suspectum venom, differs from exendin-3 by only 2 N-terminal amino acid substitutions. This polypeptide causes an increase in acinar cAMP without stimulating amylase release. Exendin-4 and glucagon-like peptide 1 (7-36) amide bind with similar affinity to the glucagon-like peptide 1 receptor. Moreover, exendin-4 is also considered for clinical use in the treatment of type 2 diabetes. |